Objective: To observe the effect and clinical significance of circulating endothelial cells (CEC) in the pathogenesis of coronary heart disease with unstable angina pectoris (CHD-UAP), and to explore the protective ef...Objective: To observe the effect and clinical significance of circulating endothelial cells (CEC) in the pathogenesis of coronary heart disease with unstable angina pectoris (CHD-UAP), and to explore the protective effect of Chinese herbs for activating blood circulation, removing stasis and supplementing Qi (CH) on CHD-UAP patient's CEC. Methods: Sixty patients with diagnosis of CHD-UAP confirmed and differentiated to be Qi-deficiency and blood stasis by TCM were randomly divided into two groups and treated, on the basis of Western drug-therapy, with Tongxinluo capsule (通心络胶囊, TXL) and Huoxue Tongmai capsule (活血通脉胶囊, HXTM) respectively by way of oral taking three times a day, 3 capsules every time, with 1 month as one therapeutic course. The number of CEC in patients' blood circulation was counted before and after treatment. Besides, the number of CEC in 30 healthy persons was also counted for control. Results: The number of CEC in CHD-UAP patients was significantly higher than that in the healthy persons (P<0.01). After the patients were treated with CH, either TXL or HXTM, it significantly decreased (P<0.01)with insignificant difference between the two treated groups. Conclusion: CEC in CHD-UAP patients is severely damaged and endothelial function in disorder, Chinese herbs have protective effect on patients' CEC.展开更多
目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为...目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。展开更多
目的对活血化瘀中药治疗氯吡格雷抵抗的有效性及安全性进行系统评价。方法检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文期刊(VIP)、中国生物医学文献库(SinoMed)、Embase、PubMed、Cochrane Library、Web of science等数据库自...目的对活血化瘀中药治疗氯吡格雷抵抗的有效性及安全性进行系统评价。方法检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文期刊(VIP)、中国生物医学文献库(SinoMed)、Embase、PubMed、Cochrane Library、Web of science等数据库自建库至2023年2月7日关于活血化瘀类中药治疗氯吡格雷抵抗患者的随机对照试验(RCT)。严格按照纳入和排除标准进行文献筛选,并进行数据提取,使用RevMan 5.4软件对纳入文献进行Meta分析。结果共纳入17篇文献,涉及患者1684例,试验组844例,对照组840例。Meta分析显示,试验组二磷酸腺苷(ADP)诱导的血小板聚集率显著低于对照组[SMD=-1.04,95%CI(-1.32,-0.76),P<0.00001];试验组在改善ADP诱导血小板聚集抑制率[SMD=3.99,95%CI(1.33,6.65),P=0.003]、血小板抑制率[SMD=0.91,95%CI(0.44,1.37),P=0.0001]、残余血小板活性单位(PRU)[MD=-17.66,95%CI(-28.55,-6.76),P=0.001]、残余血小板反应指数(PRI)[MD=-5.9,95%CI(-10.11,-1.70),P=0.006]以及残余血小板纤维蛋白凝块强度(ADPMA)[MD=-4.25,95%CI(-6.02,-2.84),P<0.00001]疗效均显著优于对照组;同时,试验组患者的再住院率[RR=0.54,95%CI(0.34,0.86),P=0.009]及缺血事件发生率显著低于对照组[RR=0.45,95%CI(0.26,0.78),P=0.004],而不增加出血风险[RR=0.64,95%CI(0.37,1.10),P=0.10],且2组普通不良反应差异无统计学意义[RR=0.69,95%CI(0.31,1.57),P=0.38]。结论活血化瘀中药防治氯吡格雷抵抗有确切的临床疗效,且安全性较好。但纳入RCT的低质量使得结论可信度下降,亟需更多高质量的RCT验证。展开更多
文摘Objective: To observe the effect and clinical significance of circulating endothelial cells (CEC) in the pathogenesis of coronary heart disease with unstable angina pectoris (CHD-UAP), and to explore the protective effect of Chinese herbs for activating blood circulation, removing stasis and supplementing Qi (CH) on CHD-UAP patient's CEC. Methods: Sixty patients with diagnosis of CHD-UAP confirmed and differentiated to be Qi-deficiency and blood stasis by TCM were randomly divided into two groups and treated, on the basis of Western drug-therapy, with Tongxinluo capsule (通心络胶囊, TXL) and Huoxue Tongmai capsule (活血通脉胶囊, HXTM) respectively by way of oral taking three times a day, 3 capsules every time, with 1 month as one therapeutic course. The number of CEC in patients' blood circulation was counted before and after treatment. Besides, the number of CEC in 30 healthy persons was also counted for control. Results: The number of CEC in CHD-UAP patients was significantly higher than that in the healthy persons (P<0.01). After the patients were treated with CH, either TXL or HXTM, it significantly decreased (P<0.01)with insignificant difference between the two treated groups. Conclusion: CEC in CHD-UAP patients is severely damaged and endothelial function in disorder, Chinese herbs have protective effect on patients' CEC.
文摘目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。
文摘目的对活血化瘀中药治疗氯吡格雷抵抗的有效性及安全性进行系统评价。方法检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文期刊(VIP)、中国生物医学文献库(SinoMed)、Embase、PubMed、Cochrane Library、Web of science等数据库自建库至2023年2月7日关于活血化瘀类中药治疗氯吡格雷抵抗患者的随机对照试验(RCT)。严格按照纳入和排除标准进行文献筛选,并进行数据提取,使用RevMan 5.4软件对纳入文献进行Meta分析。结果共纳入17篇文献,涉及患者1684例,试验组844例,对照组840例。Meta分析显示,试验组二磷酸腺苷(ADP)诱导的血小板聚集率显著低于对照组[SMD=-1.04,95%CI(-1.32,-0.76),P<0.00001];试验组在改善ADP诱导血小板聚集抑制率[SMD=3.99,95%CI(1.33,6.65),P=0.003]、血小板抑制率[SMD=0.91,95%CI(0.44,1.37),P=0.0001]、残余血小板活性单位(PRU)[MD=-17.66,95%CI(-28.55,-6.76),P=0.001]、残余血小板反应指数(PRI)[MD=-5.9,95%CI(-10.11,-1.70),P=0.006]以及残余血小板纤维蛋白凝块强度(ADPMA)[MD=-4.25,95%CI(-6.02,-2.84),P<0.00001]疗效均显著优于对照组;同时,试验组患者的再住院率[RR=0.54,95%CI(0.34,0.86),P=0.009]及缺血事件发生率显著低于对照组[RR=0.45,95%CI(0.26,0.78),P=0.004],而不增加出血风险[RR=0.64,95%CI(0.37,1.10),P=0.10],且2组普通不良反应差异无统计学意义[RR=0.69,95%CI(0.31,1.57),P=0.38]。结论活血化瘀中药防治氯吡格雷抵抗有确切的临床疗效,且安全性较好。但纳入RCT的低质量使得结论可信度下降,亟需更多高质量的RCT验证。